FDA Panel Backs Novel Treatment for Postpartum Depression

Share this post

Vote was nearly unanimous that the benefits of brexanolone outweigh risks, but only when used within a strict Risk Evaluation and Mitigation Strategies (REMS) program.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply